The American Journal of Pathology, Vol. 187, No. 5, May 2017
ajp.amjpathol.org
IMMUNOPATHOLOGY AND INFECTIOUS DISEASES
Association of Cardiac Galectin-3 Expression,
Myocarditis, and Fibrosis in Chronic Chagas
Disease Cardiomyopathy
Bruno Solano de Freitas Souza,*y Daniela Nascimento Silva,y Rejane Hughes Carvalho,y Gabriela Louise de Almeida Sampaio,y
Bruno Diaz Paredes,y Luciana Aragão França,y Carine Machado Azevedo,*y Juliana Fraga Vasconcelos,*y
Cassio Santana Meira,*y Paulo Chenaud Neto,y Simone Garcia Macambira,*yz Kátia Nunes da Silva,y Kyan James Allahdadi,y
Fabio Tavora,x João David de Souza Neto,x Ricardo Ribeiro dos Santos,y and Milena Botelho Pereira Soares*y
From the Gonçalo Moniz Research Center,* Oswaldo Cruz Foundation (FIOCRUZ), Salvador; the Center for Biotechnology and Cell Therapy,y São Rafael
Hospital, Salvador; the Health Sciences Institute,z Federal University of Bahia, Salvador; and Messejana Heart and Lung Hospital,x Fortaleza, Brazil
Accepted for publication
January 19, 2017.
Address correspondence to
Milena Botelho Pereira Soares,
Ph.D., Centro de Pesquisas
Gonçalo Moniz, Fundação
Oswaldo Cruz, Rua Waldemar
Falcão, 121, Candeal, Salvador,
Bahia, Brazil CEP: 40296710. E-mail: milena@bahia.
fiocruz.br.
Chronic Chagas disease cardiomyopathy, caused by Trypanosoma cruzi infection, is a major cause of
heart failure in Latin America. Galectin-3 (Gal-3) has been linked to cardiac remodeling and poor
prognosis in heart failure of different etiologies. Herein, we investigated the involvement of Gal-3 in
the disease pathogenesis and its role as a target for disease intervention. Gal-3 expression in mouse
hearts was evaluated during T. cruzi infection by confocal microscopy and flow cytometry analysis,
showing a high expression in macrophages, T cells, and fibroblasts. In vitro studies using Gal-3
knockdown in cardiac fibroblasts demonstrated that Gal-3 regulates cell survival, proliferation, and
type I collagen synthesis. In vivo blockade of Gal-3 with N-acetyl-D-lactosamine in T. cruzieinfected
mice led to a significant reduction of cardiac fibrosis and inflammation in the heart. Moreover, a
modulation in the expression of proinflammatory genes in the heart was observed. Finally, histological
analysis in human heart samples obtained from subjects with Chagas disease who underwent heart
transplantation showed the expression of Gal-3 in areas of inflammation, similar to the mouse model.
Our results indicate that Gal-3 plays a role in the pathogenesis of experimental chronic Chagas disease,
favoring inflammation and fibrogenesis. Moreover, by demonstrating Gal-3 expression in human hearts,
our finding reinforces that this protein could be a novel target for drug development for Chagas cardiomyopathy. (Am J Pathol 2017, 187: 1134e1146; http://dx.doi.org/10.1016/j.ajpath.2017.01.016)
Chronic Chagas disease cardiomyopathy (CCC), caused by
Trypanosoma cruzi infection, is an important cause of
morbidity and mortality in endemic countries. It is estimated
that approximately 7 million people are infected worldwide,
with high prevalence in Latin America and growing incidence in developed countries because of globalization.1,2 It
is estimated that the cardiac form of the disease occurs in
approximately 20% to 30% of infected subjects.2 Antiparasitic drugs are effective during acute infection, but fail to
improve established CCC.3,4 Besides standard heart failure
treatment, patients with advanced CCC rely on heart transplantation, which is limited because of organ availability
and complications relative to parasite reactivation after
immunosuppression therapy.5
During CCC, cardiomyocytes are lost as a result of
damage caused by immune responses directed to the parasites that persist in the heart, as well as to autoreactive cells
directed to heart antigens.6,7 Although the mechanisms of
pathogenesis are not completely understood, several studies
indicate the involvement of type 1 helper T-cell lymphocytes associated with high production of interferon-g
(IFN-g), resembling a delayed hypersensitivity reaction.6
An association between progression to severe chronic
forms and a high production of IFN-g was observed in
Supported by National Council for Scientific and Technological Development and Bahia Research Foundation.
Disclosures: None declared.
Copyright ª 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajpath.2017.01.016
Role of Galectin-3 in Chagas Disease
patients with Chagas disease.8 Macrophages, a major cell
population found in the inflammatory sites, can be activated
by IFN-g and tumor necrosis factor-a, two inflammatory
cytokines overexpressed in the hearts of mice chronically
infected with T. cruzi. Furthermore, several genes related to
the inflammatory response are up-regulated in heart tissue
during the chronic phase of T. cruzi infection.9
Previous studies suggested that activated macrophages
secrete galectin-3 (Gal-3), a molecule involved in the
pathogenesis of cardiac dysfunction.10 Gal-3 is a soluble
b-galactoside binding lectin involved in a variety of cellular
processes, including proliferation, migration, and
apoptosis.11 The importance of this protein in the regulation
of cardiac fibrosis and remodeling has been highlighted by
the demonstration of its contribution to the development and
progression of heart failure in different experimental
settings.12e14 Serum Gal-3 concentrations are also increased
in patients with acute decompensated heart failure. On the
basis of these findings, the value of Gal-3 as a prognostic
biomarker in patients with chronic heart failure has been
investigated.15
Previously, we performed transcriptomic analysis in the
cardiac tissue of mice chronically infected with T. cruzi, and
found that Lgals3, the gene encoding for Gal-3, is among
the most overexpressed genes.16 By immunofluorescence
analysis, we showed that Gal-3 is mainly expressed in
inflammatory cells in the hearts of T. cruzieinfected mice.
We hypothesized that Gal-3 plays a role in the pathogenesis
of CCC, contributing to the progression of inflammation and
fibrosis. In the present study, we evaluated the expression of
Gal-3 during T. cruzi infection in mice. Gal-3 expression
was also investigated in human heart samples, to validate
the expression of this protein in the human disease setting.
Finally, we conducted in vitro and in vivo studies involving
genetic and pharmacological blockades of Gal-3 to investigate its potential role in disease pathogenesis and its
usefulness as a target for therapeutic development.
Materials and Methods
Animal Procedures
Six- to eight-week-old female C57BL/6 mice were used for
T. cruzi infection and as normal controls. Galectin-3
C57BL/6 mice were used in cell adhesion experiments.
All animals were raised and maintained at the animal facility
of the Center for Biotechnology and Cell Therapy, Hospital
São Rafael, in rooms with controlled temperature
(22 C 2 C) and humidity (55% 10%), and continuous
air flow. Animals were housed in a 12-hour light/12-hour
dark cycle (6AM to 6PM) and provided with standard
rodent diet and water ad libitum. Animals were handled
according to the NIH guidelines for animal experimentation.17 All procedures described had prior approval from the
local institutional animal ethics committee at Hospital São
Rafael (01/13).
The American Journal of Pathology
-
ajp.amjpathol.org
Trypanosoma cruzi Infection
Trypomastigotes of the myotropic Colombian T. cruzi strain
were obtained from culture supernatants of infected LLCMK2 cells, as previously described.9 Infection of C57BL/6
mice was performed by i.p. injection of 1000 T. cruzi trypomastigotes in saline, and was confirmed through evaluation of
parasitemia at different time points after infection.
Pharmacological Blockade of Gal-3 with N-Lac
C57Bl/6 female mice (n Z 11) chronically infected with
T. cruzi [6 months postinfection (m.p.i.)] were treated with
N-acetyl-D-lactosamine (N-Lac) (Sigma-Aldrich, St. Louis,
MO), 5 mg/kg per day, i.p. injections 3 per week, for 60
days. Chronically infected mice injected with saline (n Z 10)
and same age naïve mice (n Z 8) served as controls. Functional analyses were performed, as described below. Mice
were euthanized, by cervical dislocation under anesthesia
with 5% ketamine (König, São Paulo, Brazil) and 2% xylazine (König Lab), the week after the final N-Lac injection.
Heart samples were collected for real-time quantitative PCR
and histological analysis. In another experiment, sucrose
(Sigma-Aldrich) was administered in the same regimen as
N-Lac to C57BL/6 mice, after 6 months of infection with
T. cruzi. Heart samples were collected for histological analysis.
Functional Analysis
Electrocardiography was performed using the Bio Amp
PowerLab System (PowerLab 2/20; ADInstruments,
Sydney, Australia), recording the bipolar lead I. All animals
were anesthetized by i.p. injection of 10 mg/kg xylazine and
100 mg/kg ketamine to obtain the records. All data
were acquired for computer analysis using Chart 5 for
Windows (ADInstruments). The electrocardiographic analysis included heart rate, PR interval, P wave duration, QT
interval, QTc, and arrhythmias. The QTc was calculated as
the ratio of QT interval by square roots of RR interval.
A motor-driven treadmill chamber for one animal (LE
8700; Panlab, Barcelona, Spain) was used to exercise the
animals. The speed of the treadmill and the intensity of the
shock (mA) were controlled by a potentiometer (LE 8700
treadmill control; Panlab). After an adaptation period in the
treadmill chamber, the mice exercised at five different velocities (7.2, 14.4, 21.6, 28.8, and 36.0 m/minute), with
increasing velocity after 5 minutes of exercise at a given speed.
Velocity was increased until the animal could no longer sustain a given speed and remained >5 seconds on an electrified
stainless-steel grid. Total running distance was recorded.
Morphometric Analysis
Two months after the therapy, mice were euthanized as
mentioned before and hearts were collected and fixed in
10% buffered formalin. Heart sections were analyzed by
1135
Souza et al
light microscopy after paraffin embedding, followed by
standard hematoxylin and eosin staining. Inflammatory
cells infiltrating heart tissue were counted using a digital
morphometric evaluation system. Images were digitized using
the slide scanner ScanScope (Leica, Wetzlar, Germany).
Morphometric analyses were performed using Image Pro Plus
software version 7.0 (Media Cybernetics, Rockville, MD).
The inflammatory cells were counted in 10 fields (400
magnification) per heart sample. The percentage of fibrosis
was determined using Sirius redestained heart sections and
the Image Pro Plus version 7.0. Two blinded investigators
performed the analyses (J.F.V. and C.M.A.).
Immunofluorescence Analysis
Frozen (10 mm thick) or formalin-fixed, paraffin-embedded
(3 mm thick) heart sections were obtained. Paraffin-embedded
tissues were deparaffinized and submitted to a heat-induced
antigen retrieval step by incubation in citrate buffer
(pH Z 6.0). Then, sections were incubated overnight at 4 C
with the following primary antibodies: antieGal-3, diluted
1:400 (Santa Cruz Biotechnology, Dallas, TX) and antiCD11b, diluted 1:400 (BD Biosciences, San Jose, CA). Next,
the sections were incubated for 1 hour with secondary antibodies anti-goat IgG Alexa Fluor 488-conjugated and anti-rat
IgG Alexa Fluor 594-conjugated (1:400; ThermoFisher Scientific, Waltham, MA). Immunostaining for in vitro experiments was performed in cardiac fibroblasts or bone
marrowederived macrophages plated on coverslips. The
cells were fixed with paraformaldehyde 4% and incubated
with the primary antibodies: goat antieGal-3, diluted 1:400
(Santa Cruz Biotechnology), or rabbit anti-collagen type I,
diluted 1:50 (Novotec, Lyon, France). On the following day,
sections were incubated for 1 hour with phalloidin conjugated
with Alexa Fluor 633 or 488 conjugated, diluted 1:50, mixed
with the secondary antibodies anti-goat IgG Alexa Fluor 488conjugated (1:400) or anti-rabbit IgG Alexa Fluor 568conjugated (1:200; all from ThermoFisher Scientific),
respectively. Nuclei were stained with DAPI (VectaShield
mounting medium with DAPI H-1200; Vector Laboratories,
Burlingame, CA). The presence of fluorescent cells was
determined by observation on a FluoView 1000 confocal
microscope (Olympus, Tokyo, Japan) and A1þ confocal
microscope (Nikon, Tokyo, Japan). Quantifications of
Gal-3þ cells were performed in 10 random fields captured
under 400 magnification, using the Image Pro Plus software
version 7.0.
Flow Cytometry Analysis
Control and T. cruzieinfected mice were euthanized, hearts
were collected, perfused with phosphate-buffered saline (PBS)
to remove blood cells, and processed by enzymatic digestion
using 0.1% collagenase IV (Sigma-Aldrich) and 10 mg/mL
DNase (Roche, Basel, Switzerland), for 40 minutes, at 37 C.
To evaluate the subpopulations of digested cardiac tissue
1136
samples, cell suspensions were allowed to pass through a
70-mm cell strainer (BD Biosciences) and counted. Aliquots of
106 cells were used for each test tube and 1 mL of Fc blocking
reagent (BD Biosciences) was added. The fluorochromeconjugated antibody panels used for each subpopulation
were: i) T lymphocytes: CD45-APC-Cy7, CD3-APC, CD4PE-Cy5, CD8-PE (BD Biosciences); ii) macrophages:
CD45-APC-Cy7, CD11b-APC (eBiociences, San Diego,
CA); iii) fibroblast/fibrocyte: CD45-APC-Cy7, vimentin-APC
(Cell Signaling, Danvers, MA). Each antibody was diluted as
suggested on the product data sheet. Samples were incubated
for 20 minutes at room temperature in the dark. For intracellular staining of Gal-3, samples were washed once in PBS and
CytoFix/CytoPerm kit (BD Biosciences) were used as directed
on data sheet protocol. AntieGal-3ePE (R&D Systems,
Minneapolis, MN) antibody was added to macrophages and
fibroblast/fibrocyte sample tubes, whereas nonconjugated
antieGal-3 (Santa Cruz Biotechnology) was added on
T lymphocyte sample tube and its detection was performed by
addition of anti-mouse IgG-Alexa Fluor 488 (ThermoFisher
Scientific). Each incubation step was performed during 30
minutes at room temperature in the dark. Samples were
washed twice and resuspended in PBS and added with
Hoecsht 33258 to exclude cell debris from analysis. Apoptosis
was evaluated by annexin V-PI assay. Cells were harvested
from culture flasks by adding TrypLE solution (ThermoFisher
Scientific) and incubating for 5 minutes at 37 C. Cell suspensions were collected and washed with PBS by centrifugation at 300 g. After discarding supernatant, pellets were
resuspended in binding buffer (ThermoFisher Scientific) and
cells were counted. Apoptosis assays were performed using
annexin-V-APC and PI (BD Biosciences) according to the
manufacturer’s recommendations. Sample acquisition was
performed using a BD LSRFortessa SORP cytometer (BD
Biosciences) using BD FacsDiva software version 6.2 (BD
Biosciences). Ten thousand events were acquired per sample,
and the data were analyzed using FlowJo software version 7.5
(FlowJo Enterprise, Ashland, OR).
Real-Time RT-PCR
Total RNA was isolated from heart samples with TRIzol
reagent (ThermoFisher Scientific) and the concentration was
determined by spectrophotometry. High Capacity cDNA
Reverse Transcription Kit (ThermoFisher Scientific) was
used to synthesize cDNA of 1 mg RNA following manufacturer’s recommendations. Real-time RT-PCR assays
were performed to detect the expression levels of Tbet
(Mm_00450960_m1), Gata3 (Mm_00484683_m1), Tnf
(Mm_00443258_m1), Ifng (Mm_00801778_m1), Il10
(Mm_00439616_m1), Foxp3 (Mm_00475162_m1), Lgals3
(Mm_00802901_m1), and MMP9 (Mm_00444299_m1).
Other primer sequences used in real-time PCR analyses: Col1a1: 50 -GTCCCTCGACTCCTACATCTTCTGA30 (forward) and 50 -AAACCCGAGGTATGCTTGATCTGTA0 (reverse); Ccnd1: 50 -TCCGCAAGCATGCACAGA-30
ajp.amjpathol.org
-
The American Journal of Pathology
Role of Galectin-3 in Chagas Disease
(forward) and 50 -GGTGGGTTGGAAATGAACTTCA-30
(reverse); Cav1: 50 -GGCACTCATCTGGGGCATTTA-30
(forward) and 50 -CTCTTGATGCACGGTACAACC-30
(reverse). The real-time RT-PCR amplification mixtures
contained a 20 hg template cDNA, TaqMan Master Mix (10
mL) and probes, constituting a final volume of 20 mL (all from
ThermoFisher Scientific). All reactions were run in duplicate
on an ABI7500 Sequence Detection System (ThermoFisher
Scientific) under standard thermal cycling conditions. The
mean Ct values from duplicate measurements were used to
calculate expression of the target gene, while normalized to an
internal control (Gapdh) using the 2eDCt formula. Experiments with CVs >5% were excluded. A nontemplate control
and nonreverse transcription controls were also included.
fibroblasts were transduced with the lentivirus by overnight
incubation in medium containing lentiviral particles and
6 mg/mL polybrene. Knockdown efficiency for each shRNA
was evaluated by real-time quantitative PCR using
TaqMan probes for Lgals3 (mm00802901_m1), Gapdh
(mm99999915_g1), Actb (mm00607939_s1), and Hprt
(mm00496968_m1) and TaqMan Universal PCR master
mix (ThermoFisher Scientific), according to the manufacturer’s instructions. Assay was performed in triplicate, and
the empty vector was used as control. Ct for Lgals3 was
normalized taking into account the geometric mean of the Ct
for Gapdh, Actb, and Hprt (DCt). The relative expression
was then calculated by the normalized Ct between each
Lgals3 shRNA construct and the empty vector (DDCt).
Design of shRNAs and Production of Lentiviral Vectors
In Vitro Studies with Cardiac Fibroblasts and Bone
MarroweDerived Macrophages
To stably knock down Lgals3 expression, we designed
shRNA against different regions of the Lgals3 coding
sequence, and a scramble shRNA as control. Target sequences were designed using the online tool siRNA Wizard
software version 3.1 (Invivogen, San Diego, CA). All suggested sequences were blasted against the mouse RNA
reference sequence database, and the three with the lowest
degree of homology to other sequences were selected:
Lgals3_shRNA1 50 -GATTTCAGGAGAGGGAATGAT-30 ;
Lgals3_shRNA2 50 -GGTCAACGATGCTCACCTACT-30 ;
Lgals3_shRNA3 50 -CATGCTGATCACAATCATGG-30 ;
and one Lgals3_scrbl_shRNA 50 -AGGTATGAGTCGAGATTGAGA-30 . Sense and antisense single strands, containing the target sequence, a loop sequence (TCAAGAG),
and restriction enzyme sites for Mlu at the sense sequence and
ClaI at the antisense sequence, were synthesized separately.
The annealing of both strands to form double-stranded
shRNAs was performed by incubating 2.5 mmol/L from the
sense and antisense strand of each shRNA in 10 mmol/L TrisHCl (pH 7.5), 0.1 mol/L NaCl, and 1 mmol/L EDTA at 95 C
for 5 minutes and then allowing the reaction to cool down to
room temperature for at least 2 hours. The double-stranded
shRNAs were then phosphorylated using T4 PNK (New England Biolabs, Ipswich, MA) following manufacturer protocol.
The shRNAs were cloned into the pLVTHM lentiviral vector
(Addgene plasmid 12247), specifically designed for gene
knockdown with shRNAs,18 after the vector was linearized by
digestion with MluI and ClaI (New England Biolabs) according to the manufacturer instructions. Each of the produced
shRNA constructs were confirmed by sequencing using ABI
3500 platform (ThermoFisher Scientific).
For lentiviral vector production, HEK293 FT cells were
cotransfected with each of the shRNA constructs, plus
psPAX2 (Addgene plasmid 12260) and pMD2.G (Addgene
plasmid 12247) for production of the lentivirus particles, in
a proportion of 3:2:1. Viral supernatants were harvested 48
and 72 hours later, pooled, centrifuged to remove cell
debris, filtered through 0.45-mm filters (Millipore, Billerica,
MA), and concentrated by ultracentrifugation. Cardiac
The American Journal of Pathology
-
ajp.amjpathol.org
Cardiac fibroblasts were isolated from hearts of adult
C57BL/6 mice, euthanized as described above. Hearts were
minced into pieces of 1 mm and incubated with 0.1%
collagenase type A (Sigma-Aldrich) at 37 C for 30 minutes,
under constant stirring. The cell suspension was passed
through a 70-mm cell strainer (BD Biosciences), and plasticadherent cells were selected by 1 hour incubation in gelatincoated flasks (Sigma-Aldrich). Nonadherent cells from
supernatant were removed and adherent cells were cultured
with Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum and 1% penicillin and streptomycin (all from ThermoFisher Scientific), in a humidified
incubator at 37 C with 5% CO2. Culture medium was
changed every 3 days, and cells were trypsinized (trypsinEDTA 0.05%; ThermoFisher Scientific) when 80% confluence was reached. Cell cycle studies were performed with
CFSE Cell Proliferation Kit (ThermoFisher Scientific),
according to the manufacturer’s instructions. Proliferation of
cardiac fibroblasts was assessed by the measurement of
3
H-thymidine uptake. Cells were plated in 96-well plates, at
a density of 104 cells/well, in a final volume of 200 mL, in
triplicate, and cultured in the absence or presence of 30 mg/mL
rmGal-3 (R&D Systems), with or without 1% modified
citrus pectin (ecoNugenics, Santa Rosa, CA). After 24 hours,
plates were pulsed with 1 mCi of methyl-3H thymidine
(PerkinElmer, Waltham, MA) for 18 hours, and proliferation
was assessed by measurement of 3H-thymidine uptake by
using a Chameleon b-plate counter (Hydex, Turku, Finland).
Proliferation capacity of Gal-3 knockdown and control cell
lines was compared by 3H-thymidine incorporation, using the
same procedures.
To obtain macrophages, bone marrow cells were harvested
from femurs of C57BL/6 mice by flushing with cold RPMI
1640 medium. Bone marrow cells were induced to differentiate into macrophages by culture in RPMI 1640 supplemented with 10% fetal bovine serum (ThermoFisher
Scientific), 50 U/mL of penicillin, 50 mg/mL of streptomycin,
2.0 g/L of sodium bicarbonate, 25 mmol/L HEPES, 2 mmol/L
1137
Souza et al
glutamine, and 30% supernatant obtained from X63-GMCSF19 cell line culture, at 37 C and 5% CO2. Cells were
cultured for 7 days, with half medium changes every 3 days.
Differentiated macrophages were plated onto 24-well plates
and incubated in medium alone or with 1 mg/mL lipopolysaccharide (Sigma-Aldrich) with or without 50 ng/mL IFN-g
(R&D Systems). After 24 hours, macrophages were detached
using a cell scraper and analyzed for Gal-3 expression by flow
cytometry, as described above.
Human Samples
The procedures involving human samples received prior
approval by the local Ethics committee at Hospital São
Rafael (approval number 51025115.3.0000.0048). Samples
were obtained at Messejana Hospital in Fortaleza, Ceará, a
medical center specialized for heart transplantation in
Brazil. Fragments of explanted hearts from three patients
with Chagas disease, confirmed by serological assay, were
obtained from left ventricle and septum. Samples were
processed in paraffin and stained with hematoxylin and
eosin and Sirius Red, or used for immunostaining for
detection of Gal-3, as described above.
Lymphoproliferation Assay
Splenocyte suspensions, obtained from C57Bl/6 mice, were
prepared in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum and 50 mg/mL of
gentamicin. Splenocytes were cultured in 96-well plates at
1 106 cells/well, in triplicate, and lymphocyte proliferation was stimulated or not with concanavalin A (2 mg/mL;
Sigma-Aldrich) or Dynabeads mouse T-activator CD3/
CD28 (ThermoFisher Scientific), according to the manufacturer’s instructions. Cell proliferation was induced in the
absence or presence of various concentrations of N-Lac
(10, 1, and 0.1 mmol/L). After 48 hours of incubation, 1 mCi
of 3H-thymidine was added to each well, and the plate was
incubated for 18 hours. Plates were frozen at 70 C, then
thawed and transferred to UniFilter-96 GF/B PEI coated
plates (PerkinElmer) with the assistance of a cell harvester.
After drying, 50 mL of scintillation cocktail was added in
each well, sealed and plate read at liquid scintillation
microplate counter. Dexamethasone (Sigma-Aldrich;
10 mmol/L) was used as positive control. Three independent
experiments were performed.
En Face Leukocyte Adhesion Assay
The aorta from the thoracic region and spleens were
removed from wild-type and galectin-3 knockout C57BL/6
mice. Fragments of approximately 1 mm2 were placed with
the intimal side up in 96-well plates previously coated with
Matrigel (Corning Inc., Corning, NY) for 30 minutes at
37 C. Endothelium was activated by incubation with
500 ng/mL lipopolysaccharide (Sigma), whereas the splenocyte suspension with 2 mg/mL concanavalin A (Sigma)
Figure 1 Gal-3 is overexpressed in mouse
hearts after Trypanosoma cruzi infection. Confocal
microscopy analysis demonstrated the presence of
Gal-3þ cells (green), mainly in areas of inflammatory infiltrates, in naïve (A), at 1 (B) and 6 (C)
months postinfection (m.p.i.). Cardiac muscle was
stained for actin-F (red), and nuclei were stained
with DAPI (blue). D: The cardiac expression of
Gal-3 peaked at 1 m.p.i., but remained elevated
during the chronic phase of infection, when
compared to naïve mice. E: A similar pattern is
observed for the number of inflammatory cells
infiltrating the heart. F: However, the percentage
of fibrosis increased with time. G: Most cells
expressing Gal-3 (green) coexpressed the monocyte/macrophage marker CD11b (red). H: Cardiac
fibroblasts isolated by enzymatic digestion of
heart tissue also express Gal-3 (green). Actin-F is
seen in red, and nucleus in blue. I: Bone marrowe
derived macrophages stimulated in vitro with
proinflammatory (M1) inductors interferon-g
(IFN-g) and lipopolysaccharide (LPS) increase the
expression of Gal-3. Data are expressed as means
SEM. *P < 0.05, **P < 0.01, and ***P < 0.001.
Scale bars Z 50 mm. dpi, days postinfection.
1138
ajp.amjpathol.org
-
The American Journal of Pathology
Role of Galectin-3 in Chagas Disease
Figure 2
Gal-3 is increased in different cell
types involved in inflammation and tissue repair.
Histograms showing flow cytometry analysis from
digested heart tissue, obtained from naïve and
infected mice, at 3 and 15 months postinfection
(m.p.i.). Gal-3þ T CD4þ and CD8þ lymphocytes
expressing Gal-3 are increased at 3 and 15 m.p.i.
when compared to naïve controls. Most macrophages (CD45þ/CD11bþ), fibroblasts (CD45/
vimentinþ), and bone marrowederived fibrocytes
(CD45þvimentinþ) express Gal-3 (>90%) in all
groups, but the mean fluorescence intensity increases with time of infection.
and 500 ng/mL lipopolysaccharide, during a period of
6 hours.
Activated splenocytes were incubated with 1 mmol/L
Celltracker Fluorescent Probes (Life Technologies) in
serum-free RPMI 1640 medium (Gibco) for 30 minutes and
washed three times, before adhesion to the endothelium.
Splenocytes (5 105/well) were plated and incubated with
the aortic endothelium fragments for 30 minutes at 37 C in
the presence or absence of 10 mmol/L N-Lac (SigmaAldrich). Plates were then carefully washed three times
with warm Hanks’ balanced salt solution to remove the
nonadherent cells. Three replicates were used for each
treatment. Different random areas per well were acquired
using a digital camera from an inverted fluorescence microscope. Fluorescent cells were quantified using
ImagePro.
Inhibition of Cell Migration Assay
C57BL/6 mice, 8 to 12 weeks old, were submitted to
euthanasia by cervical dislocation under anesthesia. Spleens
The American Journal of Pathology
-
ajp.amjpathol.org
were collected, minced, cells were resuspended in PBS and
passed through a 70-mm cell strainer. The cells were
resuspended and maintained in RPMI 1640 medium
(ThermoFisher Scientific), without serum, supplemented
with 2 mmol/L L-glutamine (ThermoFisher Scientific), 0.1%
RMPI 1640 vitamin solution (Sigma Aldrich), 1 mmol/L
sodium pyruvate, 10 mmol/L HEPES, 50 mmol/L
2-mercaptoetanol, and penicillin/streptomycin solution (all
from ThermoFisher Scientific). Splenocytes were incubated
in starvation during 24 hours at 37 C and 5% CO2, in the
presence or absence of 10 mmol/L N-Lac. Migration assay
was performed using the QCM Chemotaxis Cell Migration
Assay, 24-well 3-mm pore (Millipore), according to the
manufacturer’s instructions. Briefly, splenocytes were
counted and 107 cells in 250 mL were placed in the upper
chamber, in serum-free medium, in the presence or absence
of N-Lac. RPMI 1640 medium supplemented with 10%
fetal bovine serum (ThermoFisher Scientific) with or
without 10 mmol/L N-Lac was placed in the bottom chamber. Cells present in the bottom chamber were counted after
overnight incubation.
1139
Souza et al
Statistical Analysis
All continuous variables are presented as means SEM.
Continuous variables were tested for normal distribution using
Kolmogorov-Smirnov test. Parametric data were analyzed
using unpaired t tests, for comparisons between two groups, and
one-way analysis of variance, followed by Bonferroni post hoc
test for multiple-comparison test, using Prism 6.0 (GraphPad,
La Jolla, CA). P < 0.05 was considered statistically significant.
Results
Gal-3 Expression Is Increased during Experimental
T. cruzi Infection
We first analyzed the expression of Gal-3 in mouse heart
sections obtained at different time points of infection.
Trypanosoma cruzi infection led to increased expression of
Gal-3þ cells in the myocardium compared to naïve controls, as
shown by confocal microscopy (Figure 1, AeC). Quantification of Gal-3 expression showed a significant increase in all
time points analyzed, in comparison with uninfected controls
(Figure 1D). The number of Gal-3þ cells was higher at the peak
of parasitemia (1 m.p.i.), when an intense acute inflammatory
response is found in the heart (Figure 1E). The numbers of
Gal-3þ cells during the chronic phase were sustained, whereas
the percentage of fibrosis increased with time (Figure 1F). The
population of Gal-3þ cells in the heart included macrophages
(CD11bþ cells) (Figure 1G) and cardiac fibroblasts
(Figure 1H). To investigate the role of proinflammatory signals
in the expression of Gal-3 by macrophages, we performed
in vitro studies to analyze the expression of Gal-3 in activated
macrophages. Bone marrowederived macrophages activated
with IFN-g and Toll-like receptor 4 ligand lipopolysaccharide
had an increased expression of Gal-3, as demonstrated by flow
cytometry analysis (Figure 1I).
To better characterize the cell populations expressing Gal-3,
we performed flow cytometry analysis of cells isolated from
hearts of T. cruzieinfected mice (Figure 2). Both CD4þ and
CD8þ T cells had increased Gal-3 expression at 3 and 15 m.p.i.
when compared to uninfected controls. In addition, macrophages, characterized as CD45þ/CD11bþ, composed the cell
populations expressing the higher mean fluorescence intensity
of Gal-3 (Figure 2). Gal-3 was expressed at low levels in
fibroblasts (vimentinþ/CD45) in control hearts, and was
increased by 52.5% at 3 m.p.i. Gal-3 expression intensity in
fibroblasts at 15 m.p.i. returned to levels similar to those found
in controls. However, a significant increase in Gal-3 expression was detected in a population of vimentinþ/CD45þ cells,
characterized as bone marrowederived fibrocytes, at 3 and
15 m.p.i., when compared to controls (Figure 2).
Expression of Gal-3 in the Hearts of Subjects with CCC
To evaluate if the presence of Gal-3þ cells in the myocardium of infected mice could be translatable to the human
1140
Figure 3 Gal-3 expression in heart samples from subjects with end-stage
Chagas cardiomyopathy. Representative images obtained from explanted
heart sections of two subjects with end-stage Chagas cardiomyopathy who
underwent heart transplantation. Heart sections were stained with hematoxylin and eosin, showing inflammatory infiltrates composed of mononuclear cells surrounding myofibers (A) and in areas of myocytolysis (B).
Heart sections stained with Sirius red showing areas of mild (C) and
extensive (D) cardiac fibrosis. E and F: Confocal microscopy analysis from two
different subjects, showing Gal-3þ cells (red) in areas of inflammatory infiltrates. Nuclei are stained with DAPI (blue). Scale bars Z 50 mm (AeC, E,
and F); 25 mm (D).
disease, we performed analysis in human heart samples obtained from explants of subjects with chronic Chagas disease
cardiomyopathy who underwent heart transplantation. Heart
sections were prepared and stained with hematoxylin and
eosin for histological analysis, demonstrating the presence of
foci of myocarditis, with an inflammatory infiltrate composed
mainly of mononuclear cells, leading to the destruction of
myofibers (Figure 3, A and B). In addition, an extensive area
of diffuse fibrotic scar was found in Sirius redestained sections (Figure 3, C and D). The expression of Gal-3 in human
heart samples was evaluated by analysis using confocal microscopy. We observed the presence of cells, within the inflammatory foci and surrounding the myofibers, expressing
variable levels of Gal-3 (Figure 3, E and F).
Gal-3 Is a Major Regulator of Fibroblast Function
On the basis of the findings of increased Gal-3 expression in
fibroblasts during the development of CCC, we performed
in vitro studies aiming at investigating the role of Gal-3 on
different aspects of the biology of these cells. Cardiac
ajp.amjpathol.org
-
The American Journal of Pathology
Role of Galectin-3 in Chagas Disease
Figure 4 Gal-3 is crucial for cardiac fibroblast
proliferation and survival. Recombinant Gal-3 was
added to the cardiac fibroblast culture medium and
cell proliferation was measured by 3H-thymidine
incorporation assay. A: Extracellular Gal-3 induced
cardiac fibroblast proliferation, which is abolished
by addition of modified citrus pectin, a Gal-3
binding partner. B: Gal-3 knockdown in cardiac
fibroblasts markedly reduces cell proliferation, as
evaluated by 3H-thymidine incorporation assay.
C: A reduction in gene expression of cyclin D1 is
found by real-time quantitative PCR analysis. Cell
cycle analysis was performed by flow cytometry
with carboxyfluorescein succinimidyl ester assay,
demonstrating that Gal-3 knockdown in cardiac
fibroblasts is associated with cell cycle arrest in G0/
G1 phases (D) and reduced number of cells in the S
(E) and G2/M (F) phases. G: Gal-3 knockdown is
associated with increased frequency of apoptosis,
as evaluated by annexin V assay. Data are
expressed as means SEM. *P < 0.05,
**P < 0.01, and ***P < 0.001. CPM, counts per
minute; PI, propidium iodide.
fibroblasts isolated from mouse hearts were incubated with
mouse recombinant Gal-3 to evaluate their proliferative rate.
We found that exogenous recombinant Gal-3, at a micromolar concentration, increased the proliferation of cardiac
fibroblasts, whereas addition of modified citrus pectin, a
binding partner of Gal-3, blocked the effect of Gal-3
(Figure 4A).
Considering that this effect was observed at high concentrations of exogenous Gal-3, and given the high
expression of intracellular Gal-3 in cardiac fibroblasts in
experimental CCC, we evaluated the role of endogenous
Gal-3 in cardiac fibroblasts. We generated lentiviral vectors
encoding shRNA targeting the Lgals3, together with green
fluorescence protein expression as a reporter gene. Then,
cardiac fibroblasts were transduced by lentiviral infection,
resulting in the knockdown of Gal-3. The efficiencies of
lentiviral infection and knockdown were confirmed by green
fluorescence protein reporter gene expression and by
quantification of Gal-3 gene and protein expressions by realtime quantitative PCR and immunofluorescence analysis,
respectively (>90%) (Supplemental Figure S1, AeE). More
important, Gal-3 knockdown in cardiac fibroblasts led to a
down-regulation of type I collagen expression
(Supplemental Figure S1, FeH).
Gal-3 knockdown was associated with a significant
reduction in the proliferative rate of cardiac fibroblasts
(Figure 4B). This finding was accompanied by a reduction
of cyclin D1 gene expression (Figure 4C). Analysis of
caveolin-1 gene expression did not show alterations when
The American Journal of Pathology
-
ajp.amjpathol.org
control or Gal-3 knockdown cells were compared (data not
shown). Flow cytometry analysis showed cell cycle arrest in
Gal-3 knockdown when compared to control cells
(increased percentage of G0/G1 and decreased S and G2/M
phases) (Figure 4, DeF).
To determine whether Gal-3 knockdown also affects cell
survival, we evaluated the frequency of apoptosis in the
culture of cardiac fibroblasts, by annexin V/PI staining and
flow cytometry analysis. A higher percentage of apoptotic
cells was detected in cultures of cardiac fibroblasts with
Gal-3 knockdown when compared to controls (Figure 4G).
Treatment with the Gal-3 Blocking Agent N-Lac
Reduces Inflammation and Fibrosis in Experimental
CCC
To study the role of Gal-3 on the pathogenesis of CCC, we
performed a pharmacological blockade of Gal-3 using
N-Lac (Figure 5A), during the chronic phase of the infection, when cardiac fibrosis is significantly increased (6 and 8
m.p.i.). We performed functional evaluations (electrocardiographic analysis and treadmill test) before treatment
(6 m.p.i.) and after the treatment with N-Lac (8 m.p.i.).
Trypanosoma cruzi infection caused the development of
arrhythmias and cardiac conduction disturbances, such as
atrioventricular block, ventricular tachycardia, and ventricular bigeminy. Treatment with N-Lac did not alter the
frequencies or the severity of arrhythmias when compared to
those found in saline-treated controls (Table 1). Regarding
1141
Souza et al
Figure 5
In vivo pharmacological blockade of
Gal-3 during the chronic phase of experimental
Trypanosoma cruzi infection reduces inflammation
and fibrosis. A: Experimental design. B: A lack of
functional recovery was observed by analysis of
performance in treadmill test 2 months after the
beginning of treatment with N-Lac. C: A significant
reduction in the intensity of cardiac inflammation
and fibrosis is observed in heart sections of mice
treated with N-Lac stained with hematoxylin and
eosin (top row) and Sirius red (bottom row).
Quantifications of the number of inflammatory cells
infiltrating the heart (D), cardiac fibrosis area (E),
showing histological improvement in N-Lac treated
mice. Data are expressed as means SEM.
*P < 0.05, **P < 0.01, and ***P < 0.001. Original magnification, 200 (C). m.p.i., months
postinfection.
the exercise capacity, T. cruzieinfected mice had an
impaired performance when compared to uninfected controls 6 months after infection (data not shown). N-Lac
treatment did not cause any improvement in exercise
capacity, because mice treated with this Gal-3 blocker had
similar performance in treadmill test to saline-treated mice
and a reduced capacity when compared to uninfected controls (Figure 5B).
Histological analysis demonstrated the presence of
inflammatory infiltrate in the hearts of mice infected with
T. cruzi, mainly composed of mononuclear cells. The
number of inflammatory cells infiltrating the heart, however,
was significantly reduced in N-Lacetreated mice, compared
to saline-treated controls (Figure 5, C and D). In addition,
the percentage of heart fibrosis was significantly reduced
after N-Lac treatment when compared to saline-treated mice
(Figure 5, C and E). In addition, a control experiment was
performed in which T. cruzieinfected mice were treated in
1142
the same regimen with sucrose. Morphometric analysis in
the hearts of sucrose-treated mice did not show reduction of
inflammatory cells and the fibrotic area in sucrose-treated
mice when compared to those treated with saline
(Supplemental Figure S2).
To investigate whether N-Lac caused modulation of
inflammatory mediators, we performed gene expression
analysis in the heart tissue (Figure 6). N-Lacetreated mice
had reduced gene expression of the inflammatory cytokines
tumor necrosis factor-a and IFN-g when compared to
saline-treated mice. The regulatory cytokine IL-10 was
increased in T. cruzieinfected mice when compared to
uninfected controls, both in saline as well as in N-Lace
treated mice. Moreover, the gene expression of transcription
factors T-bet, GATA-3, and FoxP3, associated with T-cell
subtypes type 1 helper T cell, type 2 helper T cell, and T
regulatory cell, respectively, was increased by T. cruzi
infection and reduced in mice treated with N-Lac. The gene
ajp.amjpathol.org
-
The American Journal of Pathology
Role of Galectin-3 in Chagas Disease
Table 1 ECG Analysis in Uninfected and Trypanosoma cruzie
Infected Mice
ECG findings
Uninfected Pretreatment Saline
N-Lac
(n Z 7)
(n Z 19)
(n Z 9) (n Z 10)
No alterations
7/7
Atrial overload
IACD
JR
AVB first degree
AVB third degree
SVT
Ventricular
bigeminy
Isorhythmic AVD
AVD
IVCD
1/19
1/19
1/9
2/9
1/9
3/9
2/9
1/9
1/19
6/19
5/19
2/19
2/19
1/9
1/9
1/9
1/19
2/10
3/10
1/10
3/10
1/10
AVB, atrioventricular block; AVD, atrioventricular dissociation; ECG,
electrocardiography; IACD, intra-atrial conduction delay; IVCD, intraventricular conduction delay; JR, junctional rhythm; N-Lac, N-acetyl-Dlactosamine; SVT, supraventricular tachycardia.
expression of chemokine ligand 8 (modified citrus pectin 2)
and the chemokine receptor CCR5, which are increased by
T. cruzi infection, was also reduced after N-Lac treatment.
More important, treatment with N-Lac reduced the gene
expression of Gal-3 in the hearts of T. cruzieinfected mice
(Figure 6).
To better investigate the mechanisms by which N-Lac
caused reduction of inflammation, we performed lymphoproliferation and migration assays. Mouse splenocytes were
stimulated in vitro with concanavalin A or anti-CD3/CD28.
Addition of N-Lac at the highest concentration tested
(10 mmol/L) caused a small reduction of lymphoproliferation stimulated by both polyclonal activators (Figure 7, A
and B). In contrast, the positive control dexamethasone
inhibited the proliferation induced by both stimuli. Last, we
tested the effects of N-Lac in adhesion of leukocytes to the
endothelium and in cell migration. The adhesion of leukocytes to aorta endothelium in an en face assay was significantly blocked by N-Lac using cells and endothelium from
wild-type mice, but not from galectin-3 knockout mice
(Figure 7C). In fact, cell adhesion of galectin-3 knockout
mice was similar to that of pharmacological blockade with
N-Lac in wild-type cells (Figure 7C), In addition, the
presence of N-Lac significantly inhibited leukocyte migration in a transwell system (Figure 7D).
Discussion
Gal-3 is a multifunctional lectin that can be found in various
cells and tissues, and is detected in the nucleus, cytoplasm,
as well as in the extracellular compartment.11 Notably,
Gal-3 may have different, concordant, or opposite actions
depending on the cell type and whether it is present in the
extracellular or intracellular compartments.11 Previous
studies from our group and others have shown a correlation
between inflammation and fibrosis in the heart and Gal-3
expression.16,32,34 Moreover, host expression of Gal-3 is
required for T. cruzi adhesion and invasion in human cells.20
In the present study, we demonstrated the expression of Gal3 in different cell populations and its role in the promotion
Figure 6
Modulation of gene expression in
chagasic heart after N-Lac treatment. real-time
RT-PCR analysis of gene expression in the heart
tissue demonstrates that N-Lac treatment is
associated with a reduction of inflammatory
cytokines tumor necrosis factor (TNF)-a (A) and
interferon (IFN)-g (B), and does not alter the
expression of IL-10 (C), when compared to salinetreated mice. T-lymphocyte subtypeespecific
transcription factors associated with type 1 helper
T cell (T-bet; D), type 2 helper T cell (GATA-3; E),
and T regulatory cell (FOXP3; F) are reduced in
N-Lacetreated mice. The expression of genes
associated with leukocyte migration and chemotaxis CCR5 (G), chemokine ligand 8 (H), and
Gal-3 (I) is also reduced after N-Lac treatment.
Data are expressed as means SEM. *P < 0.05,
**P < 0.01, and ***P < 0.001.
The American Journal of Pathology
-
ajp.amjpathol.org
1143
Souza et al
Figure 7
Effects of N-Lac on splenocyte proliferation and migration in vitro. Mouse splenocytes obtained from naïve C57Bl/6 mice were
stimulated with concanavalin A (Con A; A) or antiCD3/CD28 (B) in the absence or presence of N-Lac
or dexamethasone (Dexa; 10 mmol/L). Lymphoproliferation was assessed by 3H-thymidine
uptake. C: En face adhesion assay was performed
using aorta fragments and splenocytes from wildtype or Gal-3 knockout mice, in the absence or
presence of N-Lac. Data show the frequency of
adherent cells 30 minutes after incubation.
D: Mouse splenocytes were submitted to starvation and placed in the upper compartment of a
transwell system in the presence or absence of 10
mmol/L N-Lac. Medium with or without fetal
bovine serum (FBS) was placed in the lower
chamber as a chemoattractant. Cell concentration
in the lower chamber after overnight incubation.
Data are expressed as means SEM (AeD).
*P < 0.05, **P < 0.01, and ***P < 0.001. CPM,
counts per minute.
of heart inflammation and fibrosis in T. cruzieinfected mice.
This was achieved by the following: i) immunostaining in
chronic Chagas disease human and mouse heart samples
showing the presence of Gal-3þ cells, including macrophages, T cells, fibroblasts, and fibrocytes; ii) blockade of
Gal-3 expression in cardiac fibroblasts, showing its role on
proliferation and collagen production; and iii) pharmacological blockade in vivo in the experimental model, showing
significant reduction of inflammation, fibrosis, and production of key inflammatory mediators in the heart.
Previous studies have highlighted a role for Gal-3 in the
cardiac remodeling process in different experimental
settings, including experimental models of hypertrophic
cardiomyopathy and myocardial infarction.12e14 These
reports have focused on Gal-3 effects in cardiac fibroblasts,
contributing to cell survival, proliferation, and extracellular
matrix synthesis. In CCC, however, a massive infiltration of
immune cells is observed in the heart, which leads to
persistent immune-mediated myocyte damage, ultimately
triggering a progressive fibrogenic response.6e9
In the present study, we demonstrated the dynamic
expression of Gal-3 in different periods during T. cruzi
experimental infection and correlated with the findings of
human heart analysis, in sections obtained from hearts of
subjects with end-stage heart failure due to CCC. Gal-3
expression was observed in a similar pattern in human and
mouse heart samples, mainly in areas of inflammatory
infiltrates. Gal-3 has been previously described in immune
cells and to participate in different aspects of innate and
adaptive immune responses.21e26 In the experimental
model, we showed expression of Gal-3 in macrophages and
1144
T cells, two main cell types present in the inflammatory foci
in Chagas disease hearts. Moreover, we demonstrated that
inflammatory stimuli increase the expression of Gal-3 in
macrophages in vitro. Because IFN-g and tumor necrosis
factor-a are produced in mouse hearts chronically infected
with T. cruzi, their action may account for the increased
Gal-3 expression in macrophages. The described roles for
Gal-3 in T-cell biology include the promotion of cell
survival, proliferation, T-cell receptor signaling, and
migration.27 In our study, we observed reduction of cell
adhesion to endothelium and migration, but not of
lymphocyte proliferation, by the Gal-3 inhibitor N-Lac,
suggesting that the reduction of inflammation in the hearts
of infected mice after N-Lac treatment is mainly because of
reduction of cell migration.
In our study, we found that T. cruzi infection also
increased the expression of Gal-3 in cardiac fibroblasts and,
even more intensely, in a population of bone marrowe
derived fibrocytes. Although cardiac fibroblasts have been
classically described as the most important cell type
involved in cardiac fibrosis, different studies have shown
that bone marrowederived fibrocytes play relevant roles in
fibrogenesis and remodeling.28e30 Our data provided from
in vitro assays in cardiac fibroblasts demonstrated the role of
exogenous and endogenous Gal-3 in cell survival, proliferation, and type I collagen synthesis, which is supported by
the current literature.12e14 The fact that extracellular Gal-3
increased cell proliferation only in high concentration and
the marked reduction of proliferation in Gal-3 knockdown
cells indicate that intracellular Gal-3 has a critical role in
cell proliferation regulation. Interestingly, Gal-3 has been
ajp.amjpathol.org
-
The American Journal of Pathology
Role of Galectin-3 in Chagas Disease
previously shown to enhance cyclin D1 promoter activity,31
correlating with the cell cycle arrest and decreased expression of cyclin D1 gene in Gal-3 knockdown fibroblasts
found in our study. The fact that caveolin-1 gene expression
was not increased in Gal-3 knockdown cells reinforces a
direct action of Gal-3 in the regulation of cyclin D1 gene
transcription.
We have previously shown that Lgals3 gene expression is
up-regulated in the hearts of mice during chronic T. cruzi
infection.9,16 The correlation between intensity of myocarditis and presence of collagen type I, Gal-3, and a-smooth
muscle actinepositive cells was also seen in a mouse model
of T. cruzi infection.32 Gal-3 was implicated in the process
of T. cruzi invasion.33 Altogether, these data suggest that
Gal-3 is involved in different aspects of the pathogenesis of
CCC, from T. cruzi infection to immune response, inflammation, and tissue repair. Interestingly, a reduction of Gal-3
expression in the heart was observed accompanying
decreased fibrosis and myocarditis after granulocyte colonystimulating factor treatment or cell therapy in chronically
infected mice.16,34 In the present study, we showed that the
Gal-3 pharmacological blockade with N-Lac significantly
modulated the immune response in the hearts from CCC
mice, reducing migration of immune cells to the myocardium and decreasing the expression of inflammatory type 1
helper T-cell cytokines and markers of type 2 helper T-cell
and T regulatory cell lymphocyte subtypes, to the level of
naïve control mice. Notably, the anti-inflammatory cytokine
IL-10 was increased when compared to naïve mice. This
finding, together with the observed reduced levels of IFNG
and TNFA gene expression, demonstrates a potent antiinflammatory effect of N-Lac. Moreover, N-Lac treatment
was associated with a significant reduction of myocardial
fibrosis, which is in accordance with a previous report in a
different experimental model.14 Despite the reduction of
inflammation and fibrosis, our results did not correlate with
any improvement in functional parameters after N-Lac
treatment. This finding does not exclude the possibility of
long-term beneficial effects of Gal-3 blockade, nor that
N-Lac treatment, at an earlier stage of the infection, which
may prevent the deterioration of cardiac function.
The strong binding affinity between galectin-3 and
N-acetyl-D-lactosamine has been previously reported.35
Moreover, in previous studies, similar dose and administration regimen of N-acetyl-D-lactosamine were used to
block galectin-3 in mouse models of viral myocarditis36 and
hypertensive cardiac remodeling.14 The reduction of
inflammation and fibrosis observed after N-Lac treatment
were not observed in mice treated with sucrose in the same
dose and regimen. Moreover, pharmacological (by N-Lac)
and genetic (gene knockout) blockade of Gal-3 had similar
effects in cell adhesion to endothelium, and indicate that
N-Lac does not interfere with selectin binding.
In a translational perspective, Gal-3 could be used in the
clinical setting as either a novel biomarker or a therapeutic
target. Although the identification of novel noninvasive
The American Journal of Pathology
-
ajp.amjpathol.org
biomarkers that adequately predict cardiac fibrosis would be
highly desired, in a recent report we showed that plasma
Gal-3 levels do not correlate with the intensity of fibrosis, as
measured by magnetic resonance imaging, in a recently
published transversal study in subjects with CCC.37 Nonetheless, these data do not exclude the possibility of Gal-3
being useful as a biomarker for prognosis determination,
which is currently under investigation in chronic heart
failure caused by other etiologies.38 Thus, the conduction of
a longitudinal study in Chagas disease subjects would be
required to validate the use of plasma Gal-3 as prognosis
biomarker.
In conclusion, herein, we demonstrated that Gal-3 plays
an important role in the pathogenesis of experimental
chronic Chagas disease, acting in different cell compartments and promoting cardiac inflammation and fibrosis. The
finding of Gal-3 expression in human heart samples, in a
similar pattern as observed in the mouse model, reinforces
its potential as a novel target for drug and therapy development for CCC.
Acknowledgments
We thank Pamela Daltro for technical assistance in the
cardiac functional analysis, Didier Trono for pLVTHM
lentiviral vector, Dr. Luiz R. Goulart for providing galectin-3
knockout mice, and Drs. Igor Correia de Almeida and
Washington Luis Conrado dos Santos for helpful discussions.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2017.01.016.
References
1. Andrade DV, Gollob KJ, Dutra WO: Acute Chagas disease: new
global challenges for an old neglected disease. PLoS Negl Trop Dis
2014, 8:e3010
2. WHO: Chagas disease in Latin America: an epidemiological update
based on 2010 estimates. Wkly Epidemiol Rec 2015, 90:33e44
3. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA,
Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV,
Gilman RH, Reyes PA, Salvatella R, Moore AC: Evaluation and
treatment of Chagas disease in the United States: a systematic review.
JAMA 2007, 298:2171e2181
4. Morillo CA, Marin-Neto JA, Avezum A; BENEFIT Investigators:
Randomized trial of Benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med 2015, 373:1295e1306
5. Burgos JM, Diez M, Vigliano C, Bisio M, Risso M, Duffy T, Cura C,
Brusses B, Favaloro L, Leguizamon MS, Lucero RH, Laguens R,
Levin MJ, Favaloro R, Schijman AG: Molecular identification of
Trypanosoma cruzi discrete typing units in end-stage chronic Chagas
heart disease and reactivation after heart transplantation. Clin Infect
Dis 2010, 51:485e495
6. Soares MB, Pontes-De-Carvalho L, Ribeiro-Dos-Santos R: The pathogenesis of Chagas’ disease: when autoimmune and parasite-specific
immune responses meet. An Acad Bras Cienc 2001, 73:547e559
1145
Souza et al
7. Bonney KM, Engman DM: Autoimmune pathogenesis of Chagas heart
disease: looking back, looking ahead. Am J Pathol 2015, 185:1537e1547
8. Gomes JA, Bahia-Oliveira LM, Rocha MO, Martins-Filho OA,
Gazzinelli G, Correa-Oliveira R: Evidence that development of severe
cardiomyopathy in human Chagas’ disease is due to a Th1-specific
immune response. Infect Immun 2003, 71:1185e1193
9. Soares MB, de Lima RS, Rocha LL, Vasconcelos JF, Rogatto SR, dos
Santos RR, Iacobas S, Goldenberg RC, Iacobas DA, Tanowitz HB, de
Carvalho AC, Spray DC: Gene expression changes associated with
myocarditis and fibrosis in hearts of mice with chronic chagasic cardiomyopathy. J Infect Dis 2010, 202:416e426
10. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van
Veldhuisen DJ: Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009, 11:811e817
11. Krzeslak A, Lipi
nska A: Galectin-3 as a multifunctional protein. Cell
Mol Biol Lett 2004, 9:305e328
12. Sharma U, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP,
Schroen B, André S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM:
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004,
110:3121e3128
13. González GE, Cassaglia P, Noli Truant S, Fernández MM, Wilensky L,
Volberg V, Malchiodi EL, Morales C, Gelpi RJ: Galectin-3 is essential
for early wound healing and ventricular remodeling after myocardial
infarction in mice. Int J Cardiol 2014, 176:1423e1425
14. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, van
der Harst P, Pitt B, Goldstein IJ, Koerts JA, van Veldhuisen DJ,
Bank RA, van Gilst WH, Silljé HH, de Boer RA: Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013, 6:107e117
15. Chen A, Hou W, Zhang Y, Chen Y, He B: Prognostic value of serum
galectin-3 in patients with heart failure: a meta-analysis. Int J Cardiol
2015, 182:168e170
16. Soares MBP, Lima RS, Souza BSF, Vasconcelos JF, Rocha LL, dosSantos RR, Iacobas S, Goldenberg RC, Lisanti MP, Iacobas DA,
Tanowitz HB, Spray DC, Campos-de-Carvalho AC: Reversion of gene
expression alterations in hearts of mice with chronic chagasic cardiomyopathy after transplantation of bone marrow cells. Cell Cycle 2011,
10:1448e1455
17. Committee for the Update of the Guide for the Care and Use of
Laboratory Animals; National Research Council: Guide for the Care
and Use of Laboratory Animals: Eighth Edition. Washington, DC,
National Academies Press, 2011
18. Wiznerowicz M, Trono D: Conditional suppression of cellular genes:
lentivirus vector-mediated drug-inducible RNA interference. J Virol
2003, 77:8957e8961
19. Karasuyama H, Melchers F: Establishment of mouse cell lines which
constitutively secrete large quantities of interleukins 2, 3, 4, or 5 using
modified cDNA expression vectors. Eur J Immunol 1988, 18:97e104
20. Kleshchenko YY, Moody TN, Furtak VA, Ochieng J, Lima MF,
Villalta F: Human galectin-3 promotes Trypanosoma cruzi adhesion to
human coronary artery smooth muscle cells. Infect Immun 2004, 72:
6717e6721
21. Henderson NC, Sethi T: The regulation of inflammation by galectin-3.
Immunol Rev 2009, 230:160e171
22. Hsu DK, Yang RY, Pan Z, Yu L, Salomon DR, Fung-Leung WP,
Liu FT: Targeted disruption of the galectin-3 gene results in attenuated
peritoneal inflammatory responses. Am J Pathol 2000, 156:1073e1083
1146
23. Jeon SB, Yoon HJ, Chang CY, Koh HS, Jeon SH, Park EJ: Galectin-3
exerts cytokine-like regulatory actions through the JAK-STAT
pathway. J Immunol 2010, 185:7037e7046
24. MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC,
Atkinson KM, Leffler H, Nilsson UJ, Haslett C, Forbes SJ, Sethi T:
Regulation of alternative macrophage activation by galectin-3.
J Immunol 2008, 180:2650e2658
25. Yang RY, Hsu DK, Liu FT: Expression of galectin-3 modulates t-cell
growth and apoptosis. Proc Natl Acad Sci U S A 1996, 93:6737e6742
26. Chen SS, Sun LW, Brickner H, Sun PQ: Downregulating galectin-3
inhibits proinflammatory cytokine production by human monocytederived dendritic cells via RNA interference. Cell Immunol 2015,
294:44e53
27. Tribulatti MV, Figini MG, Carabelli J, Cattaneo V, Campetella O:
Redundant and antagonistic functions of galectin-1, -3, and -8 in the
elicitation of t cell responses. J Immunol 2012, 188:2991e2999
28. Chu PY, Mariani J, Finch S, McMullen JR, Sadoshima J, Marshall T,
Kaye DM: Bone marrow-derived cells contribute to fibrosis in the
chronically failing heart. Am J Pathol 2010, 176:1735e1742
29. van Amerongen MJ, Bou-Gharios G, Popa E, van Ark J, Petersen AH,
van Dam GM, van Luyn MJ, Harmsen MC: Bone marrow-derived
myofibroblasts contribute functionally to scar formation after
myocardial infarction. J Pathol 2008, 214:377e386
30. Haudek SB, Cheng J, Du J, Wang Y, Hermosillo-Rodriguez J, Trial J,
Taffet GE, Entman ML: Monocytic fibroblast precursors mediate
fibrosis in angiotensin-II-induced cardiac hypertrophy. J Mol Cell
Cardiol 2010, 49:499e507
31. Lin HM, Pestell RG, Raz A, Kim HR: Galectin-3 enhances cyclin d(1)
promoter activity through sp1 and a camp-responsive element in
human breast epithelial cells. Oncogene 2002, 21:8001e8010
32. Ferrer MF, Pascuale CA, Gomez RM, Leguizamón MS: DTU I isolates
of Trypanosoma cruzi induce upregulation of galectin-3 in murine
myocarditis and fibrosis. Parasitology 2014, 141:849e858
33. Machado FC, Cruz L, da Silva AA, Cruz MC, Mortara RA, RoqueBarreira MC, da Silva CV: Recruitment of galectin-3 during cell invasion and intracellular trafficking of Trypanosoma cruzi extracellular
amastigotes. Glycobiology 2014, 24:179e184
34. Vasconcelos JF, Souza BS, Lins TF, Garcia LM, Kaneto CM,
Sampaio GP, de Alcântara AC, Meira CS, Macambira SG,
Ribeiro-dos-Santos R, Soares MB: Administration of granulocyte
colony-stimulating factor induces immunomodulation, recruitment of
T regulatory cells, reduction of myocarditis and decrease of parasite
load in a mouse model of chronic Chagas disease cardiomyopathy.
FASEB J 2013, 27:4691e4702
35. von Mach T, Carlsson MC, Straube T, Nilsson U, Leffler H, Jacob R:
Ligand binding and complex formation of galectin-3 is modulated by
pH variations. Biochem J 2014, 457:107e115
36. Jaquenod De Giusti C, Ure AE, Rivadeneyra L, Schattner M,
Gomez RM: Macrophages and galectin 3 play critical roles in CVB3induced murine acute myocarditis and chronic fibrosis. J Mol Cell
Cardiol 2015, 85:58e70
37. Noya-Rabelo MM, Larocca TF, Macêdo CT, Torreão JA, Souza BS,
Vasconcelos JF, Souza LE, Silva AM, Ribeiro Dos Santos R,
Correia LC, Soares MB: Evaluation of Galectin-3 as a novel biomarker
for Chagas cardiomyopathy. Cardiology 2017, 136:33e39
38. Peacock WF: How galectin-3 changes acute heart failure decision
making in the emergency department. Clin Chem Lab Med 2014, 52:
1409e1412
ajp.amjpathol.org
-
The American Journal of Pathology